Show simple item record

dc.contributor.authorYu, J.Y.
dc.contributor.authorMcKenna, V.A.
dc.contributor.authorDumyati, G.K.
dc.date.accessioned2020-04-21T19:42:26Z
dc.date.available2020-04-21T19:42:26Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083051554&doi=10.1093%2fofid%2fofz544&partnerID=40&md5=eaa7920c189b62a679e74ba0bc2018e4
dc.identifier.urihttp://hdl.handle.net/10713/12624
dc.description.abstractBackground. Statewide tracking and reporting is an outpatient antimicrobial stewardship tool that may be useful for many stakeholders. However, to date, these evaluations have been limited. This study aimed to track and report outpatient antibiotic prescribing in Medicare Part B enrollees diagnosed with cystitis in the outpatient setting. Methods. This was a retrospective, cohort study of Medicare Part B enrollees in New York State. Inclusion criteria include outpatient visit in 2016 or 2017, cystitis diagnosis code, and oral antibiotic prescription ?3 days after diagnosis of cystitis. Antibiotics were categorized as first-line, oral ?-lactams, fluoroquinolones, or other per Infectious Diseases Society of America acute uncomplicated cystitis guidelines. Data were stratified by sex. Annual prescriptions proportions were compared using ?2 test or Fisher's exact test as appropriate. Results. A total of 50 658 prescriptions were included. For females' prescriptions, first line increased (41.5% vs 43.8%, P < .0001), oral ?-lactams increased (17.8% vs 20.5%, P < .0001), fluoroquinolones decreased (34.1% vs 29.1%, P < .0001), and other increased (6.5% vs 6.6%, P = .76) in 2017. For males' prescriptions, first line increased (25.2% vs 26.7%, P = .11), oral ?-lactams increased (23.1% vs 26.2%, P = .0003), fluoroquinolones decreased (44.0% vs 39.3%, P < .0001), and other remained unchanged (7.8% vs 7.8%, P = .92) in 2017. Conclusions. Guideline concordant therapy prescribing for cystitis increased among Medicare Part B beneficiaries in New York State between 2016 and 2017. However, there was still a high prevalence of fluoroquinolone prescribing. These data highlight the need for additional outpatient antimicrobial stewardship efforts in New York State. Copyright The Author(s) 2020.en_US
dc.description.sponsorshipThe analyses on which this publication is based were performed under Contract Number HHSM-500-2014-QIN013I, funded by the Centers for Medicare and Medicaid Services, an agency of the US Department of Health and Human Services.en_US
dc.description.urihttps://doi.org/10.1093/ofid/ofz544en_US
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofOpen Forum Infectious Diseases
dc.subjectAntibiotic prescribingen_US
dc.subjectNew York Stateen_US
dc.subjectOutpatient antimicrobial stewardshipen_US
dc.subjectUrinary tract infectionen_US
dc.titleAntibiotic prescribing in New York State medicare part B beneficiaries diagnosed with cystitis between 2016 and 2017en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/ofid/ofz544


This item appears in the following Collection(s)

Show simple item record